Ebola Death Toll Passes 100 in DR Congo as Rare Strain Defies Vaccines

The Ebola outbreak tearing through eastern Democratic Republic of the Congo has now claimed more than 100 lives, with the Africa Centres for Disease Control and Prevention reporting 608 confirmed cases and 102 deaths by Monday. The pathogen is the Bundibugyo strain, a rare variant first identified in Uganda in 2007, and one for which no approved vaccine or specific antiviral therapy exists. Existing stockpiles of the rVSV-ZEBOV vaccine, deployed against the more common Zaire strain, are ineffective here, leaving health authorities reliant on classic containment measures in a region where even those are extraordinarily difficult to execute.

More than 90 per cent of infections are concentrated in Ituri province, with additional clusters in North Kivu and South Kivu — territories long ravaged by armed conflict. The outbreak was officially declared on 15 May, but officials now acknowledge it circulated undetected for weeks, meaning the true case count is almost certainly higher. Cross-border transmission has already occurred: Uganda has confirmed 19 cases and two deaths, plus one probable fatal case, and has closed its frontier with Congo. The World Health Organisation warned on Tuesday that the epidemic is evolving rapidly, with increasing geographic spread and the persistent risk of further exportation to neighbouring states.

Containment is being thwarted on multiple fronts. Armed groups active in the affected provinces are impeding access for response teams, while community scepticism has at times boiled over into aggression against health workers. Africa CDC notes that only around two-thirds of known contacts are being traced, leaving significant chains of transmission unmonitored. The observed mortality rate among confirmed cases stands at roughly 17 per cent — lower than the 50–90 per cent seen in some Zaire-strain outbreaks — but analysts caution that this figure may reflect undercounting of deaths in inaccessible areas rather than a genuinely milder clinical course.

Viewed from European capitals, the crisis is mobilising fresh financial commitments. The European Commission has allocated €17.5 million to support Africa CDC’s response, and Switzerland has pledged 3 million francs. African public health officials, however, stress that funding alone cannot overcome the security and trust deficits that define this epidemic. Without a biomedical countermeasure, the playbook shrinks to isolation, contact tracing and safe burials — interventions that are notoriously fragile in conflict zones. Diplomats and epidemiologists in Geneva fear that if the virus gains a foothold in urban centres or crosses into Rwanda or South Sudan, the emergency could escalate sharply. The coming weeks will test whether a response built for the Zaire strain can adapt to a pathogen that strips away its most powerful tool.